Neurocrine Biosciences NBIX
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$1.83M (11 inflow days, 9 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 35.2% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 4.48% to 5.81% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| BlackRock | Mutual Fund | 2026/Q4 | +1,144,496 | 14.7% |
| Vestal Point Capital, LP | Hedge Fund | 2026/Q4 | +620,000 | 2.5% |
| Thrivent Investment Management, Inc. | Mutual Fund | 2026/Q4 | +526,736 | 0.8% |
| Ninety One UK Limited | Mutual Fund | 2026/Q4 | +434,610 | 0.4% |
| State Street Global Advisors | Mutual Fund | 2026/Q4 | +422,377 | 4.8% |
| KBC Asset Management NV | Mutual Fund | 2026/Q4 | +401,445 | 0.4% |
| Susquehanna International Group, LLP | Private Company | 2026/Q4 | +328,899 | 0.4% |
| Jupiter Fund Management Plc | Mutual Fund | 2026/Q4 | +252,030 | 0.2% |
| Logos Global Management, L.P. | Hedge Fund | 2026/Q4 | +250,000 | 0.2% |
| Deka Investment GmbH | Mutual Fund | 2026/Q4 | +246,868 | 0.4% |
| Victory Capital Management Inc. | Mutual Fund | 2026/Q4 | +218,607 | 0.8% |
| Bank of America Corporation | Public Company | 2026/Q4 | +207,872 | 0.4% |
| ZKB Asset Management | Mutual Fund | 2026/Q4 | +201,784 | 0.3% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q4 | +200,000 | 0.2% |
| Capital Impact Advisors, LLC | Mutual Fund | 2026/Q4 | +184,025 | 0.2% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 9 Nov 2026 | Sanjay Keswani | Former Chief Medical Officer | Intent to Sell (Form 144) | -53,614 | $167.37 | – |
| 3 Nov 2026 | Eiry Roberts | Chief Medical Officer | Other Derivative Acquisition | +1,506 | – | 1,506 |
| 3 Nov 2026 | Eiry Roberts | Chief Medical Officer | Other Derivative Acquisition | +8,314 | $166.05 | 8,314 |
| 2 Nov 2026 | George Morrow | Independent Director | Derivative Exercise and Sale | -15,000 | $168.53 | 10,386 |
| 31 Oct 2026 | Kyle Gano | Chief Executive Officer | Derivative Exercise and Sale | -332 | $146.10 | 155,010 |
| 31 Oct 2026 | Kyle Gano | Chief Executive Officer | Derivative Exercise and Retained | +282 | – | 155,010 |
| 27 Sep 2026 | Eiry Roberts | Chief Medical Officer | Initial Statement of Beneficial | +0 | – | 16,129 |
| 13 Sep 2026 | Matthew Abernethy | Chief Financial Officer | Automatic Disposition | -2,311 | $157.20 | 42,808 |
| 13 Sep 2026 | David Boyer | Chief Corporate Affairs Officer | Automatic Disposition | -826 | $157.45 | 8,722 |
| 10 Sep 2026 | Kevin Gorman | Director | Sale to Issuer | -7,839 | $156.22 | 517,797 |
| 10 Sep 2026 | Kevin Gorman | Director | Other Acquisition | +14,343 | – | 517,797 |
| 10 Sep 2026 | Julie Cooke | Chief Human Resources Officer | Sale to Issuer | -1,936 | $156.22 | 24,025 |
| 10 Sep 2026 | Julie Cooke | Chief Human Resources Officer | Other Acquisition | +3,587 | – | 24,025 |
| 10 Sep 2026 | Eric Benevich | Chief Commercial Officer | Sale to Issuer | -3,386 | $156.22 | 67,297 |
| 10 Sep 2026 | Eric Benevich | Chief Commercial Officer | Other Acquisition | +6,275 | – | 67,297 |
| 10 Sep 2026 | Jude Onyia | Chief Scientific Officer | Sale to Issuer | -1,936 | $156.22 | 22,647 |
| 10 Sep 2026 | Jude Onyia | Chief Scientific Officer | Other Acquisition | +3,587 | – | 22,647 |
| 10 Sep 2026 | Darin Lippoldt | Chief Legal Officer | Sale to Issuer | -2,419 | $156.22 | 56,793 |
| 10 Sep 2026 | Darin Lippoldt | Chief Legal Officer | Other Acquisition | +4,483 | – | 56,793 |
| 10 Sep 2026 | Kyle Gano | Chief Executive Officer | Sale to Issuer | -4,380 | $156.22 | 154,728 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 5,900,825 | 5.8% | 5.4 |
| 15 Oct 2026 | 6,447,491 | 6.3% | 4.5 |
| 30 Sep 2026 | 5,853,128 | 5.8% | 4.0 |
| 15 Sep 2026 | 4,964,907 | 4.9% | 5.4 |
| 31 Aug 2026 | 5,056,144 | 5.0% | 4.7 |
| 14 Aug 2026 | 4,551,075 | 4.5% | 3.4 |
No comments yet — be the first to weigh in on NBIX.
Sign in to join the discussion.